Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
(Stockholm, Sweden, 25 November, 2021) Inhalation Sciences AB (ISAB) has received Registered Trademarks in the US for PreciseInhale[®], its core aerosol generating system, DissolvIt[®], its unique in vitro dissolution module, and XposeALI[®], its air-liquid interface cell culturing tool. The US is a strategic target market for ISAB.
The US is the world's largest and most innovative market for inhaled pharmaceuticals. ISAB's Labtech product PreciseInhale[®] significantly reduces risk in inhaled drug development. It is currently being trialled for clinical use in humans, which would offer the unique possibility of directly establishing a correlation between the preclinical and clinical effects of drug substances. In August 2021 ISAB announced that the US patent on PreciseInhale[®][ ]had been extended until 2034.
ISAB CEO Manoush Masarrat: "The US is a highly dynamic and innovative market, and a priority one for us. This new protection underlines how unique our offering is as we continue to build business and relationships with our partners and prospects in the US."